Krish S. Krishnan, Chairman and Chief Executive Officer, and Suma M. Krishnan, President of Research and Development, will highlight these updates and Krystal’s strategic vision in a presentation at ...
The government expects the policy, supported by well-defined standard operating procedures (SOPs), to significantly boost ...
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva’s anti-IL-15 candidate, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback